Science & Enterprise subscription

Follow us on Twitter

  • AAAS report: US ranks 10th in R&D as share of GDP ...
    about 13 hours ago
  • Clinical trial results show a strategy that first tests for genomic mutations to guide treatments results in better…
    about 18 hours ago
  • New post on Science and Enterprise: Better Precision Medicine Outcomes Shown for Leukemia #Science #Business
    about 18 hours ago
  • Drug maker Eli Lilly and National Institutes of Health are stopping a clinical trial testing a synthetic antibody t…
    about 23 hours ago
  • New post on Science and Enterprise: Lilly, NIH Halt Covid-19 Antibody Therapy Trial #Science #Business
    about 23 hours ago

Please share Science & Enterprise

Patent Issued for Protein-Engineered Flu Vaccine Technology

USPTO building (


Fraunhofer USA in Newark, Delaware has been assigned a U.S. patent for its technology that binds proteins with antigens to fight influenza. The Patent and Trademark Office awarded patent 8,124,103 on 28 February to three inventors, including Vidadi Yusibov, executive director of Fraunhofer USA.

Yusibov also serves as the chief scientific officer of iBio Inc., a biopharmaceutical company in Newark that is taking the vaccine technology to market. The patent covers the Fraunhofer-developed process for fusing substances that generate antibodies against influenza called antigens with a protein known as lichenase.

This protein acts as a booster for the antigens and increases their effectiveness. The patent holders say that the fusion of lichenase to vaccine antigens can enhance duration of immune response, increase the stability of the product, and improve the economics of producing the vaccines.

The Fraunhofer process uses plants as the basis of its influenza antigens, including genetically engineered plants to produce the desired proteins. Plants, the patent notes, are relatively easy to manipulate genetically, and have some advantages over alternative animal-based sources. The patent says, however, that  the technology leaves open the option for adding animal sources, such as mammalian cell lines or bacteria, if required.

The technology can also be extended for other types of vaccines. “We previously published data demonstrating significant improvement in candidate vaccine performance in animal models when lichenase technology is employed with a range of target antigens,” says Yusibov, “including antigens from plague, malaria, and human papilloma virus.”

Read more:

*     *     *

3 comments to Patent Issued for Protein-Engineered Flu Vaccine Technology